Download PDF
Am J Perinatol 2022; 39(10): 1027-1032
DOI: 10.1055/a-1692-1039
SMFM Fellowship Series Article

The Trend of Urinary N Terminal Probrain Natriuretic Peptide in Extremely Low Birth Weight Infants during the Neonatal Period

Safdar S. Khan 
1   Division of Neonatology, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida
,
Henrietta S. Bada
2   Division of Neonatology, Department of Pediatrics, College of Medicine, University of Kentucky, Lexington, Kentucky
,
Maritza Torres
1   Division of Neonatology, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida
,
Melvin Almodovar
3   Division of Pediatric Cardiology, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida
,
Mina Hanna
2   Division of Neonatology, Department of Pediatrics, College of Medicine, University of Kentucky, Lexington, Kentucky
› Author Affiliations Funding The project described was supported by the National Center for Advancing Translational Sciences, UL1TR000117, the Dean of the College of Medicine, University of Kentucky, and Children's Miracle Network (CMN) grant awarded to Kentucky Children's Hospital; U.S. Department of Health and Human Services, National Institutes of Health.
› Further Information
    Permissions and Reprints

Abstract

Objective N-terminal probrain natriuretic peptide (NT-proBNP) is a biomarker of interest in many cardiopulmonary diseases in extremely low birth weight (ELBW) Infants. However, there is a gap in knowledge about the trend of ELBW infant's urinary NT-proBNP during the neonatal period.

Aim To determine the trend of urinary NT-proBNP during the first 4 weeks of life of an ELBW infant.

Study Design We analyzed prospectively enrolled 87 ELBW infants. Urinary NT-proBNP to creatinine ratios were measured on days 1 to 7, 14, and 28 of life. We plotted each study point's means to determine the trend of urinary NT-proBNP over the entire neonatal period. Data were analyzed using the Friedman analysis of variance for comparative analysis of study points.

Results Urinary NT-proBNP/creatinine ratios were significantly elevated on days 1 to 7 (mean 2,452, ± 1,518) than day 14 (mean 747, ± 176), and day 28 (mean 149, ± 54), p = 0.001. Overall, urinary NT-proBNP levels were highest during days 1 to 3 (mean 3,232, ± 1,255) and lowest on day 28 (mean 149, ± 54).

Conclusion Urinary NT-proBNP levels are higher during the first week in ELBW infants with a downward trend during the neonatal period, the lowest values at 4 weeks postnatal age. More studies are required to determine the clinical utility of this trend during and beyond the neonatal period.

Key Points

  • NT-proBNP is a biomarker for monitoring cardiac disease in premature infants.

  • The trend of urinary NT-proBNP is unknown in premature infants.

  • A trend of urinary NT-proBNP was determined during the first 4 weeks in premature infants.

Keywords

NT-proBNP - trend - premature - infants


Publication History

Received: 14 September 2021

Accepted: 01 November 2021

Accepted Manuscript online:
09 November 2021

Article published online:
07 December 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 El-Khuffash A, Molloy E. The use of N-terminal-pro-BNP in preterm infants. Int J Pediatr 2009; 2009: 175216
    CrossrefPubMedGoogle Scholar
  • 2 Westerlind A, Wåhlander H, Lindstedt G, Lundberg PA, Holmgren D. Clinical signs of heart failure are associated with increased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr 2004; 93 (03) 340-345
    CrossrefPubMedGoogle Scholar
  • 3 Koch A, Zink S, Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 2006; 27 (07) 861-866
    CrossrefPubMedGoogle Scholar
  • 4 Nasser N, Perles Z, Rein AJJT, Nir A. NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis. Pediatr Cardiol 2006; 27 (01) 87-90
    CrossrefPubMedGoogle Scholar
  • 5 Cohen S, Springer C, Avital A. et al. Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress?. Pediatrics 2005; 115 (05) 1347-1350
    CrossrefPubMedGoogle Scholar
  • 6 Gessler P, Knirsch W, Schmitt B, Rousson V, von Eckardstein A. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in children with congenital heart defects and open-heart surgery. J Pediatr 2006; 148 (03) 372-376
    CrossrefPubMedGoogle Scholar
  • 7 Carmona F, Manso PH, Vicente WV, Castro M, Carlotti AP. Risk stratification in neonates and infants submitted to cardiac surgery with cardiopulmonary bypass: a multimarker approach combining inflammatory mediators, N-terminal pro-B-type natriuretic peptide and troponin I. Cytokine 2008; 42 (03) 317-324
    CrossrefPubMedGoogle Scholar
  • 8 Shalev A, Nir A, Granot E. Cardiac function in children post-orthotopic liver transplantation: echocardiographic parameters and biochemical markers of subclinical cardiovascular damage. Pediatr Transplant 2005; 9 (06) 718-722
    CrossrefPubMedGoogle Scholar
  • 9 El-Khuffash A, Barry D, Walsh K, Davis PG, Molloy EJ. Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage. Arch Dis Child Fetal Neonatal Ed 2008; 93 (06) F407-F412
    CrossrefPubMedGoogle Scholar
  • 10 Nuntnarumit P, Khositseth A, Thanomsingh P. N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants. J Perinatol 2009; 29 (02) 137-142
    CrossrefPubMedGoogle Scholar
  • 11 Farombi-Oghuvbu I, Matthews T, Mayne PD, Guerin H, Corcoran JD. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2008; 93 (04) F257-F260
    CrossrefPubMedGoogle Scholar
  • 12 Ramakrishnan S, Heung YM, Round J, Morris TP, Collinson P, Williams AF. Early N-terminal pro-brain natriuretic peptide measurements predict clinically significant ductus arteriosus in preterm infants. Acta Paediatr 2009; 98 (08) 1254-1259
    CrossrefPubMedGoogle Scholar
  • 13 Harris SL, More K, Dixon B. et al. Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus. Eur J Pediatr 2018; 177 (04) 521-532
    CrossrefPubMedGoogle Scholar
  • 14 Méndez-Abad P, Zafra-Rodríguez P, Lubián-López S, Benavente-Fernández I. NTproBNP is a useful early biomarker of bronchopulmonary dysplasia in very low birth weight infants. Eur J Pediatr 2019; 178 (05) 755-761
    CrossrefPubMedGoogle Scholar
  • 15 Khan S, Concina VA, Schneider D, Westgate P, Arriagada S, Bada H. Role of NT-proBNP in the prediction of moderate to severe bronchopulmonary dysplasia in preterm infants. Pediatr Pulmonol 2020; 55 (02) 376-382
    CrossrefPubMedGoogle Scholar
  • 16 Montgomery AM, Bazzy-Asaad A, Asnes JD, Bizzarro MJ, Ehrenkranz RA, Weismann CG. Biochemical screening for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Neonatology 2016; 109 (03) 190-194
    CrossrefPubMedGoogle Scholar
  • 17 Akcan AB, Kardelen F, Oygucu SE. et al. The efficacy of cardiac findings in assessing the outcome in preterms with bronchopulmonary dysplasia. Indian J Pediatr 2013; 80 (11) 896-902
    CrossrefPubMedGoogle Scholar
  • 18 Rodríguez-Blanco S, Oulego-Erroz I, Alonso-Quintela P, Terroba-Seara S, Jiménez-González A, Palau-Benavides M. N-terminal-probrain natriuretic peptide as a biomarker of moderate to severe bronchopulmonary dysplasia in preterm infants: a prospective observational study. Pediatr Pulmonol 2018; 53 (08) 1073-1081
    CrossrefPubMedGoogle Scholar
  • 19 Zhou L, Xiang X, Wang L, Chen X, Zhu J, Xia H. N-terminal pro-B-type natriuretic peptide as a biomarker of bronchopulmonary dysplasia or death in preterm infants: a retrospective cohort analysis. Front Pediatr 2019; 7: 166
    CrossrefPubMedGoogle Scholar
  • 20 Joseph L, Nir A, Hammerman C, Goldberg S, Ben Shalom E, Picard E. N-terminal pro-B-type natriuretic peptide as a marker of bronchopulmonary dysplasia in premature infants. Am J Perinatol 2010; 27 (05) 381-386
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Sellmer A, Hjortdal VE, Bjerre JV. et al. N-terminal pro-B type natriuretic peptide as a marker of bronchopulmonary dysplasia or death in very preterm neonates: a cohort study. PLoS One 2015; 10 (10) e0140079
    CrossrefPubMedGoogle Scholar
  • 22 Montaner A, Pinillos R, Galve Z. et al. Brain natriuretic propeptide as an early marker of bronchopulmonary dysplasia or death in the preterm newborn. Klin Padiatr 2017; 229 (04) 223-228
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Dasgupta S, Aly AM, Malloy MH, Okorodudu AO, Jain SK. NTproBNP as a surrogate biomarker for early screening of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. J Perinatol 2018; 38 (09) 1252-1257
    CrossrefPubMedGoogle Scholar
  • 24 Czernik C, Metze B, Müller C, Bührer C. Urinary NT-proBNP and ductal closure in preterm infants. J Perinatol 2013; 33 (03) 212-217
    CrossrefPubMedGoogle Scholar
  • 25 Khan SS, Sithisarn T, Bada HS, Vranicar M, Westgate PM, Hanna M. Urinary NT-proBNP levels and echocardiographic parameters for patent ductus arteriosus. J Perinatol 2017; 37 (12) 1319-1324
    CrossrefPubMedGoogle Scholar
  • 26 Naeem B, Ayub A, Aly AM, Malloy MH, Okorodudu AO, Jain SK. Urinary NT-proBNP as a potential noninvasive biomarker for screening of pulmonary hypertension in preterm infants: a pilot study. J Perinatol 2020; 40 (04) 628-632
    CrossrefPubMedGoogle Scholar
  • 27 Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332 (6159): 78-81
    CrossrefPubMedGoogle Scholar
  • 28 Yasue H, Yoshimura M, Sumida H. et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90 (01) 195-203
    CrossrefPubMedGoogle Scholar
  • 29 McDowell G, Shaw C, Buchanan KD, Nicholls DP. The natriuretic peptide family. Eur J Clin Invest 1995; 25 (05) 291-298
    CrossrefPubMedGoogle Scholar
  • 30 Davidson NC, Struthers AD. Brain natriuretic peptide. J Hypertens 1994; 12 (04) 329-336
    CrossrefPubMedGoogle Scholar
  • 31 de Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996; 31 (01) 7-18
    CrossrefPubMedGoogle Scholar
  • 32 Yandle TG. Biochemistry of natriuretic peptides. J Intern Med 1994; 235 (06) 561-576
    CrossrefPubMedGoogle Scholar
  • 33 Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009; (191) 341-366
    CrossrefPubMedGoogle Scholar
  • 34 Gobinet-Georges A, Valli N, Filliatre H, Dubernet MF, Dedeystere O, Bordenave L. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. Clin Chem Lab Med 2000; 38 (06) 519-523
    CrossrefPubMedGoogle Scholar
  • 35 Shimizu H, Aono K, Masuta K, Asada H, Misaki A, Teraoka H. Stability of brain natriuretic peptide (BNP) in human blood samples. Clin Chim Acta 1999; 285 (1-2): 169-172
    CrossrefPubMedGoogle Scholar
  • 36 Kemperman H, van den Berg M, Kirkels H, de Jonge N. B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device. Clin Chem 2004; 50 (09) 1670-1672
    CrossrefPubMedGoogle Scholar
  • 37 Nir A, Lindinger A, Rauh M. et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009; 30 (01) 3-8
    CrossrefPubMedGoogle Scholar
  • 38 Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003; 89 (08) 875-878
    CrossrefPubMedGoogle Scholar
  • 39 Mir TS, Laux R, Hellwege HH. et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 2003; 112 (04) 896-899
    CrossrefPubMedGoogle Scholar
  • 40 Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJ. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 2004; 93 (05) 603-607
    CrossrefPubMedGoogle Scholar
  • 41 Yoshibayashi M, Kamiya T, Saito Y. et al. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol 1995; 133 (02) 207-209
    CrossrefPubMedGoogle Scholar
  • 42 Roche Diagnostics. Elecsys proBNP II. In: PROBNP II, N-TERMINAL PRO B-TYPE NATRIURETIC PEPTIDE. Roche Diagnostics; https://www.rochecanada.com/content/dam/rochexx/roche-ca/products/docs/package_inserts/ElecsysproBNPII-07027664190-EN-CAN.pdf
    Google Scholar
  • 43 Czernik C, Metze B, Müller C, Müller B, Bührer C. Urinary N-terminal B-type natriuretic peptide predicts severe retinopathy of prematurity. Pediatrics 2011; 128 (03) e545-e549
    CrossrefPubMedGoogle Scholar
  • 44 Fritz AS, Keller T, Kribs A, Hünseler C. Reference values for N-terminal pro-brain natriuretic peptide in premature infants during their first weeks of life. Eur J Pediatr 2021; 180 (04) 1193-1201
    CrossrefPubMedGoogle Scholar